From the experts of hyaluronic acid

An innovation in Filler Technology

DECORIA®
Created by Nature.
Made in Sweden.
Unique Swedish research behind

An innovation in Filler Technology

For many years, traditionally cross-linked hyaluronic acid of non-animal origin has been a proven substance in dermal fillers and has been shown to be very safe and effective. We have now taken the development a big step forward. Thanks to our innovative spherification technology, a result of many years of Swedish research, we can now introduce a hyaluronic acid-based dermal filler with smooth, spherical particles instead of the traditional structure with angular rhomboids.

The name of the dermal filler is Decoria, an advanced product in which the smooth spherical particles contribute to an even smoother result – and greater patient satisfaction.

Our quality and research programme, applying comprehensive tests, has shown that this is a safe and secure product with a high degree of purity, which gives a long-lasting effect with low propensity to change.

With our extensive experience and knowledge, as well as our own R&D department and high-tech production facility, Bohus BioTech AB has since 1992 focused on developing and manufacturing premium products containing hyaluronic acid.
The visible difference with Decoria

Decoria is available in three versions:
Decoria essence
Decoria intense
Decoria voluma

All three products are easy to apply and are much appreciated among practitioners due to high patient satisfaction and the straightforward ease of use.

Frown lines
Decoria essence

Nasolabial folds
Decoria essence
Decoria intense

Cupid’s bow
Decoria essence

Lips
Decoria essence
Decoria intense

Labial commissure
Decoria essence

Facial contouring and enhancement
Decoria voluma
Decoria intense

Facial volumizer
Decoria voluma
The visible difference with Decoria is obvious.

**Application**
Decoria essence should be injected intradermally through a needle into mid dermis.

Decoria intense should be injected intradermally through a needle into the deep layer of the dermis and/or the surface layer of the subcutis.

The depth of injection with Decoria voluma may vary between injections into the subcutaneous tissue to supraperiosteal administration depending on the treatment site.

**Product description**
Decoria products are composed of cross-linked hyaluronic acid of non-animal origin and are supplied in a graded, disposable, 1.0 ml glass syringe. Two disposable sterile needles are provided with each syringe. The products are for single use only.

Decoria is only intended to be administered by authorized personnel in accordance with local legislation.
In the 1970’s a research group in Sweden worked on investigating the properties of hyaluronic acid. The results were new breakthrough products for the treatment of e.g. cataracts and osteoarthritis. Potential was also seen in the endogenous substance as a product for aesthetic correction.

One of these researchers was Daniel C. Ogbonnaya who founded the company Bohus BioTech AB in 1992 to develop products based on hyaluronic acid. Today, Bohus BioTech offers a range of their own products for cataract treatments, osteoarthritis care and aesthetic enhancement. This focus on research, development and manufacturing in its own, high-tech production facility has helped making Bohus BioTech a company with products sold in over 70 countries throughout the world.

Facts about Bohus BioTech:
- Founded in 1992 by researcher Daniel C. Ogbonnaya
- Own R&D department
- Approved manufacturing in accordance with MDD 93/42/EEC, ISO 13485
- CE 0483
- Manufacturing in ISO Class 5 – 8 cleanrooms and highly-automated, state of the art processing equipment
- Products sold in more than 70 countries throughout the world
- More than 20 formulations of products for the treatment of cataracts, osteoarthritis and aesthetic correction
“My colleagues’ and my ambition is to always be at the forefront of research and manufacture innovative products that help to develop our clients’ activities, achieve the best results for the patient, and of course be safe and easy to handle.”

Daniel C. Ogbonnaya, researcher and founder of Bohus BioTech